机构：[1]Department of Algology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China四川大学华西医院[2]Department of Algology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China[3]Department of Algology, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China[4]Department of Physiology and Pain Research Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China[5]Department of Algology, The Third People's Hospital of Yibin, Yibin 644000, Sichuan Province, China[6]Department of Algology, The Affiliated T.C.M Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China[7]Department of Algology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China[8]Department of Algology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China[9]Department of Neurosurgery, Shenzhen University General Hospital, Shenzhen 518055, Guangdong Province, China深圳大学总医院深圳市康宁医院深圳医学信息中心[10]Department of Algology, The People's Hospital of Jilin Province, Changchun 130021, Jilin Province, China[11]Department of Algology, Hubei Third People’s Hospital of Jianghan University, Wuhan 430033, Hubei Province, China[12]Department of Algology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China重庆医科大学附属第一医院[13]Department of Algology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China昆明医科大学附属第一医院[14]Department of Algology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China首都医科大学附属天坛医院
Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice, the Chinese Association for the Study of Pain organized first-line pain management experts from China to write an expert consensus as the reference for the use of ion channels drugs . Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A, pregabalin, and gabapentin. We hope this guideline provides guidance to clinicians and patients on the use of ion channel drugs for the management of NPP.
基金：
Supported by Sichuan Science and
Technology Program, No.
2018SZ0386
第一作者机构：[1]Department of Algology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
通讯作者：
通讯机构：[1]Department of Algology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China[*1]Department of Algology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Wuhou District, Chengdu 610041, Sichuan Province, China.
推荐引用方式(GB/T 7714)：
Hong Xiao,Ke Ma,Dong Huang,et al.Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain[J].WORLD JOURNAL OF CLINICAL CASES.2021,9(9):2100-2109.doi:10.12998/wjcc.v9.i9.2100.
APA：
Hong Xiao,Ke Ma,Dong Huang,Xian-Guo Liu,Tang-Hua Liu...&Yan-Qing Liu.(2021).Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain.WORLD JOURNAL OF CLINICAL CASES,9,(9)
MLA：
Hong Xiao,et al."Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain".WORLD JOURNAL OF CLINICAL CASES 9..9(2021):2100-2109
